Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Harvard Business School
McKesson
QuintilesIMS
Cantor Fitzgerald
Fish and Richardson
Farmers Insurance
Daiichi Sankyo

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

« Back to Dashboard

Clinical Trials for Bupivacaine Hydrochloride; Epinephrine

Trial ID Title Status Sponsor Phase Summary
NCT00298571 Cesarean Delivery and Post-operative Pain Management With Local Anesthesia Completed University of South Florida Phase 2/Phase 3 The use of .5% Bupivacaine with epinephrine at the time of skin closure in cesarean deliveries will decrease post-op pain.
NCT00458003 Phenylephrine in Spinal Anesthesia in Preeclamptic Patients Recruiting Northwestern University N/A Hypotension remains a common clinical problem after induction of spinal anesthesia for cesarean delivery. Maternal hypotension has been associated with considerable morbidity (maternal nausea and vomiting and fetal/neonatal acidemia). Traditionally, ephedrine has been the vasopressor of choice because of concerns about phenylephrine's potential adverse effect on uterine blood flow. This practice was based on animal studies which showed that ephedrine maintained cardiac output and uterine blood flow, while direct acting vasoconstrictors, e.g., phenylephrine, decreased uteroplacental perfusion. However, several recent studies have demonstrated that phenylephrine has similar efficacy to ephedrine for preventing and treating hypotension and may be associated with a lower incidence of fetal acidosis. All of these studies have been performed in healthy patients undergoing elective cesarean delivery. Preeclampsia complicates 5-6% of all pregnancies and is a significant contributor to maternal and fetal morbidity and mortality. Many preeclamptic patients require cesarean delivery of the infant. These patients often have uteroplacental insufficiency. Given the potential for significant hypotension after spinal anesthesia and its effect on an already compromised fetus, prevention of (relative) hypotension in preeclamptic patients is important. Spinal anesthesia in preeclamptic patients has been shown to have no adverse neonatal outcomes as compared to epidural anesthesia when hypotension is treated adequately. Due to problems related to management of the difficult airway and coagulopathy, both of which are more common in preeclamptic women, spinal anesthesia may be the preferred regional anesthesia technique. Recent studies have demonstrated that preeclamptic patients may experience less hypotension after spinal anesthesia than their healthy counterparts. To our knowledge, phenylephrine for the treatment of spinal anesthesia-induced hypotension has not been studied in women with preeclampsia. The aim of our study is to compare intravenous infusion regimens of phenylephrine versus ephedrine for the treatment of spinal anesthesia induced hypotension in preeclamptic patients undergoing cesarean delivery. The primary outcome variable is umbilical artery pH.
NCT00531349 Regional Anesthesia and Endometrial Cancer Recurrence Withdrawn The Cleveland Clinic Phase 3 The purpose of this study is to determine whether recurrence of local and metastatic cancer after open hysterectomy for stage 1 or 2 endometrial cancer is reduced when patients receive epidural anesthesia/analgesia combined with propofol sedation rather than sevoflurane anesthesia and opioid analgesia.
NCT00636415 Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis Completed Federal University of São Paulo N/A CONTEXT AND OBJECTIVE: Osteoarthritis causes pain and disability in a high percentage of elderly people. The aim of the present study was to compare the analgesic effect of intra-articular bupivacaine and morphine in patients with knee osteoarthritis. DESIGN AND SETTING: A randomized and double-blind study was performed at a Pain Clinic of São Paulo Federal University. METHODS: Thirty-nine patients with pain for more than 3 months and an intensity higher than 3 on a numerical scale (zero to 10) were included. G1 patients received 1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and G2 patients received 25 mg (10 ml) 0.25% bupivacaine without epinephrine. Pain was assessed on a numerical scale and knee flexion and extension angles were measured after administration of the drugs at rest and during movement. The total amount of analgesic complementation with 500 mg paracetamol was also determined.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bupivacaine Hydrochloride; Epinephrine

Condition Name

Condition Name for Bupivacaine Hydrochloride; Epinephrine
Intervention Trials
Pain 14
Postoperative Pain 11
Pain, Postoperative 7
Analgesia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bupivacaine Hydrochloride; Epinephrine
Intervention Trials
Pain, Postoperative 24
Osteoarthritis 8
Labor Pain 3
Fractures, Bone 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bupivacaine Hydrochloride; Epinephrine

Trials by Country

Trials by Country for Bupivacaine Hydrochloride; Epinephrine
Location Trials
United States 56
Canada 9
Brazil 6
Egypt 3
Denmark 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bupivacaine Hydrochloride; Epinephrine
Location Trials
Texas 7
California 5
New York 5
Illinois 4
Massachusetts 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bupivacaine Hydrochloride; Epinephrine

Clinical Trial Phase

Clinical Trial Phase for Bupivacaine Hydrochloride; Epinephrine
Clinical Trial Phase Trials
Phase 4 36
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bupivacaine Hydrochloride; Epinephrine
Clinical Trial Phase Trials
Completed 38
Recruiting 24
Not yet recruiting 15
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bupivacaine Hydrochloride; Epinephrine

Sponsor Name

Sponsor Name for Bupivacaine Hydrochloride; Epinephrine
Sponsor Trials
Federal University of São Paulo 6
University of Minnesota - Clinical and Translational Science Institute 4
Pacira Pharmaceuticals, Inc 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bupivacaine Hydrochloride; Epinephrine
Sponsor Trials
Other 100
U.S. Fed 6
Industry 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
QuintilesIMS
Teva
Boehringer Ingelheim
Accenture
Cerilliant
Merck
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.